Inhaled Nitric Oxide Market, By Product Type (Inhaled Nitric Oxide Delivery Systems, Consumables, (Nitric Oxide Cylinders and Delivery Accessories), and Others), By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD),

Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator approved for treating term and near-term neonates with hypoxic respiratory failure. iNO works by dilating pulmonary vessels, improving ventilation-perfusion matching, and reducing pulmonary hypertension. Upon inhalation, iNO rapidly reacts with oxygen and water in the lungs to produce nitrogen dioxide and nitrate. As these breakdown products are not lipid soluble, iNO has very little ability to enter the bloodstream and cause systemic vasodilation. This selective pulmonary vasodilation allows iNO to significantly improve oxygenation without worsening ventilation/perfusion mismatching or causing systemic hypotension in neonates with hypoxic respiratory failure.

Market Dynamics:

The global inhaled nitric oxide market growth is driven by the rising incidence of preterm births and respiratory distress syndrome among neonates. For Instance, in May 2025, according to the data reported by World Health Organization, prematurity is the leading cause of death among children under 5 years of age. Preterm birth complications caused around 900,000 child deaths in 2020, with 75% preventable through cost-effective interventions; global preterm birth rates in 2020 ranged from 4–16%. Moreover, inhaled nitric oxide has been increasingly recommended as the first-line therapy for hypoxic respiratory failure in newborns by leading clinical practice guidelines, thereby fuelling its adoption. However, the market growth can be restrained by the exorbitant price of iNO delivery systems and cylinders. On the other hand, ongoing research on the efficacy of iNO in other lung conditions like acute respiratory distress syndrome (ARDS) in adults presents lucrative opportunities for market expansion.

Key features of the study:

• This report provides in-depth analysis of the global inhaled nitric oxide market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global inhaled nitric oxide market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Mallinckrodt plc, Linde PLC, Nippon Sanso Holdings Corporation, SOL Group, Air Liquide S.A., Air Water Inc., Chemix Specialty Gases and Equipment, Vero Biotech LLC, Sichuan Salman Chemical Products Co., Ltd., Chengdu Taiyu Industrial Gases Co., Ltd., Bellerophon Therapeutics Inc., Merck KGaA, GE Healthcare, Mitsubishi Tanabe Pharma Corporation, Messer Group, Nu-Med Plus Inc., Beyond Air Inc., Praxair Technology Inc., Getinge Group, and Circassia Pharmaceuticals.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global inhaled nitric oxide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhaled nitric oxide market

• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
• Inhaled Nitric Oxide Delivery Systems
• Consumables
• Nitric Oxide Cylinders
• Delivery Accessories
• Others
• Application Insights (Revenue, USD Bn, 2020 - 2032)
• Neonatal Respiratory Treatment
• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Distress Syndrome (ARDS)
• Tuberculosis Treatment
• Malaria Treatment
• Others
• Strength Insights (Revenue, USD Bn, 2020 - 2032)
• 100 ppm
• 800 ppm
• Others
• End User Insights (Revenue, USD Bn, 2020 - 2032)
• Hospitals
• Ambulatory Surgical Centers
• Home Care Settings
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Mallinckrodt plc
• Linde PLC
• Nippon Sanso Holdings Corporation
• SOL Group
• Air Liquide S.A.
• Air Water Inc.
• Chemix Specialty Gases and Equipment
• Vero Biotech LLC
• Sichuan Salman Chemical Products Co., Ltd.
• Chengdu Taiyu Industrial Gases Co., Ltd.
• Bellerophon Therapeutics Inc.
• Merck KGaA
• GE Healthcare
• Mitsubishi Tanabe Pharma Corporation
• Messer Group
• Nu-Med Plus Inc.
• Beyond Air Inc.
• Praxair Technology Inc.
• Getinge Group
• Circassia Pharmaceuticals